Kat Kayser-Bricker

Kat Kayser-Bricker is an accomplished drug discovery leader with experience across several therapeutic areas and target families, with core expertise in small molecule cancer drug discovery. She has spent her biotech career in Connecticut working across several companies. Kat is the chief scientific officer at Halda Therapeutics, a private biotechnology company founded by Craig Crews from Yale University with the vision of creating novel medicines to cure human diseases.  This clinical-stage company has been successful in the invention and establishment of a novel drug modality called RIPTAC™ Therapeutics. Kat also recently served as an independent director on the board of Yale spinout Modifi Biosciences and BioCT, and she previously spent 10 years as a key scientific leader at FORMA Therapeutics. Kat received her PhD in organic chemistry from Yale University and her BS in biochemistry from the University of Maryland, College Park.